Abstract
Context:
Hepatocellular carcinoma (HCC) is a common disorder throughout the world that can develop due to various factors, including genetics. Tumor necrosis factor-α (TNF-α) is the most frequently studied cytokine related to the risk of developing HCC, and an association between the 308 position of the TNF-α promoter (TNF-α-308) and HCC risk has been confirmed in various reports.Evidence Acquisition:
The PubMed, Scopus, and Google Scholar databases were searched through July 12, 2015, for studies on associations between TNF-α-308 and the risk of HCC. To determine this association, odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.Results:
A total of 23 case-control studies were investigated, involving 3,389 cases and 4,235 controls. The overall conclusion was that the A allele was more frequent in case groups compared to control groups (13.4% vs. 8.4%). Thus, the A allele was significantly associated with increased HCC risk (OR = 1.77; 95% CI = [1.26-2.50]; P value < 0.002). In addition to the allelic model, the dominant model (AA + AG vs. GG) was significantly associated with HCC risk (OR = 1.80; CI = [1.29-2.51]; P value < 0.001). In the sensitivity analysis for co-dominant (AA vs. GG) and recessive models (AA vs. AG + GG), no trustworthy associations with the risk of HCC development were observed.Conclusions:
This meta-analysis indicated that the TNF-α-308 G/A polymorphism is significantly associated with increased susceptibility to HCC. However, to confirm this finding, more studies are needed on TNF-α-308 G/A polymorphisms associated with HCC.Keywords
Tumor Necrosis Factor-α Hepatocellular Carcinoma Polymorphisms TNF-α-308 Meta-Analysis
1. Context
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women (1), accounting for 70% - 85% of primary liver cancers (2). Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the main causes of HCC; however, only a fraction of patients with these infections will develop HCC during their lifetimes. The prevalence of HCC is correlated with the incidence of HBV and HCV in regions with a high risk of these infections, such as Asia and Africa, where HBV and HCV are the primary cause of HCC.
Tumor necrosis factor-α (TNF-α), which is associated with HCC susceptibility, is a multi-functional cytokine that helps to regulate different pathways involved in inflammation, immunity, apoptosis, anti-apoptosis, and tumorigenesis (3). TNF-α was first believed to be an anti-tumor cytokine, but emerging evidence does not confirm this role. New research has identified TNF-α in a majority of cancers associated with inflammation, acting as a tumor-promoting factor. Indeed, it plays two different roles associated with cancer: it can be an endogenous tumor-promoter, or it can act as a cancer-killer (4) along with activated macrophages, which are the major source of TNF-α, monocytes, lymphoid cells, and mast cells. TNF-α can also be produced by various tumor cells, including breast cancer, B-lymphoma, and colon carcinoma. Considerable research has confirmed the role of TNF-α in the promotion and progression of human cancers. It can cause activation of activator protein 1 (AP-1) and nuclear factor-kappa B (NF-κB) transcription factors through different pathways (5). In some studies, TNF-α expression was elevated in HCC patients (6, 7); however, in other studies, a lower level of TNF-α was reported in HCC patients compared to healthy controls (8, 9). The critical role of TNF-α in HBV reactivation was also recently discussed by author (10).
Many studies have been performed on the association between the frequency of susceptible TNF-α promoter alleles and HCC development. The most-studied polymorphism of TNF-α promoter positions in HCC development risk are -308 G/A, -238 G/A, -857 C/T, and -863 C/A.
Wilson et al. (11) identified a biallelic polymorphism in the TNF-α promoter at position -308 (TNF-α-308), which was introduced as G to A transition polymorphism. The A allele is significantly less common than the G allele globally. It has been suggested that TNF-α-308 influences gene expression (12). The A allele in TNF-α-308 results in a higher constitutive and inducible level of TNF expression compared to the G allele (13). All of these studies indicate the importance of TNF-α-308 polymorphisms in the risk of HCC development.
2. Evidence Acquisition
2.1. Publication Search
A systematic literature search for all published articles related to HCC and TNF-α-308 polymorphisms was conducted using the databases of PubMed, Scopus, and Google Scholar. The last search update was on July 12, 2015, using the keywords “tumor necrosis factor-α” or “tumor necrosis factor-alpha” or “TNF-α”, “polymorphism” or “genotype” or “SNP”, and “hepatocellular carcinoma” or “HCC” or “liver cancer”. The references for the selected articles were also checked for further related studies.
2.2. Selection Criteria
The inclusion criteria were:
1) The study design must be case-control.
2) The outcome should be HCC.
3) The study must include at least two groups, including a case group and a control group.
4) The frequency of alleles and genotypes for both groups, case and control, must be given or calculated.
5) The full article must be published in the English language.
Review articles, systematic reviews, and meta-analyses were excluded, but their references were checked for possible eligible studies based on the above criteria.
2.3. Data Extraction
The essential data were extracted from each article by both of the authors independently. All of the extracted data, including year of publication, country, study period, genotyping method, number of cases and controls, and frequency of genotypes and alleles, were categorized, then entered into our database. Any disagreement was discussed until a consensus was reached.
2.4. Statistical Analysis
Statistical analyses were carried out using Comprehensive Meta-Analysis (CMA) software, version 2. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the association between TNF-α-308 polymorphisms and the risk of HCC development. A P < 0.05 was considered statistically significant. Heterogeneity among the studies was examined with the Cochran Q test and I2 statistics. When significant heterogeneity was observed (pheterogeneity < 0.1 and I2 > 50%), the random effect model was used. However, in homogeneous conditions (pheterogeneity > 0.1 and I2 < 50%), the fixed-effect model was employed. Publication bias was investigated visually with funnel plots. For calculation of overall effect size in the absence of one study, a sensitivity analysis was conducted. In this meta-analysis, both the allelic and the genotype genetics models, including per-allele (A vs. G), co-dominant (AA vs. GG), dominant (AA + AG vs. GG), and recessive models (AA vs. AG + GG), were analyzed in order to evaluate the associations between the TNF-α-308 G/A allele and HCC development risk.
3. Results
3.1. Publication Search
A total of 287 articles were identified in the database search. Only articles in the English language were chosen for primary screening. After omitting 53 duplicate studies, 234 articles were considered for skimming of titles and abstracts, and 52 articles were subsequently selected for careful scanning of the context. More than half of these (29 studies) were excluded because they contained insufficient or non-relevant data for this analysis. Finally, 23 eligible studies were entered into our meta-analysis (Figure 1). In three of these studies, the GA and AA genotypes were reported in overall form instead of separately, so they could be included only in the dominant-model analysis. Table 1 shows the summary of exported data from all of the included studies.
3.2. Association Between the TNF-α-308 G/A Polymorphism Mmodels and HCC Rrisk
Figure 2 indicates the association of the allelic model (A vs. G) and the risk of HCC. Overall, the A allele was identified more frequently in HCC patients than in controls (13.4% vs. 8.4%, respectively). Talaat et al. (14) were the only authors to report a statistically significant difference from the overall result. In analyzing the allelic model, because of high heterogeneity (Pheterogeneity < 0.001, I2 = 85%), a random effect model was used. Figure 2 shows that mutant allele A in TNF-α-308 was related to increased HCC risk (P = 0.001, OR [95% CI] = 1.77 [1.26-2.50]). For the co-dominant model (AA vs. GG), considering the significant heterogeneity among the studies (Pheterogeneity = 0.003, I2 = 55%), a random-effect model was employed. The analysis of the co-dominant model (P < 0.020, OR [95% CI] =2.14 [1.13-4.06]), shown in Figure 3, identified a possible association with HCC risk, but this result may be influenced by removing one study. Therefore, we deduced that this result was not reliable.
Flow Chart for Identifying Potential Studies for the Meta-Analysis
Main Characteristics of the Studies Included in the Meta-Analysis
| Study, y | Ref | Country | Study Period | Genotyping Method | Case | Control | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | GG | GA | AA | N | GG | GA | AA | |||||
| Wang, 2003 | (15) | Japan | 2000 - 2001 | Direct sequencing | 125 | 109 | 15 | 1 | 55 | 48 | 6 | 1 |
| Ben-Ari, 2003 | (16) | Israel | NM | PCR-SSP | 10 | 9 | 1a | 48 | 42 | 6a | ||
| Heneghan, 2003 | (17) | China | NM | PCR | 98 | 88 | 10 | 0 | 172 | 158 | 13 | 1 |
| Ho, 2004 | (18) | China | 2000 - 2003 | PCR | 74 | 37 | 34 | 3 | 289 | 225 | 62 | 2 |
| Niro, 2005 | (19) | Italy | 2000 - 2003 | Direct sequencing | 30 | 24 | 6a | 96 | 75 | 21a | ||
| Migita, 2005 | (20) | Japan | 2000 - 2004 | PCR-SSP | 48 | 47 | 1 | 0 | 188 | 183 | 5 | 0 |
| Chen, 2005 | (21) | China | 1997 - 2001 | PCR-RFLP | 572 | 468 | 95 | 9 | 381 | 311 | 67 | 3 |
| Kummee, 2007 | (22) | Thailand | NM | PCR-RFLP | 50 | 42 | 6 | 2 | 150 | 123 | 15 | 12 |
| Jeng, 2007 | (23) | China | 2001 - 2001 | PCR | 108 | 80 | 28 | 0 | 108 | 100 | 8 | 0 |
| Sakamoto, 2008 | (24) | Japan | 2001 - 2004 | PCR-RFLP | 209 | 205 | 4 | 0 | 275 | 270 | 5 | 0 |
| Jeng, 2009 | (25) | China | 2003 - 2004 | PCR | 200 | 149 | 50 | 1 | 200 | 188 | 12 | 0 |
| Ognjanovic, 2009 | (26) | US | 1984 - 2001 | TaqMan | 118 | 90 | 28a | 225 | 176 | 49a | ||
| Akkiz, 2009 | (27) | Turkey | 2005 - 2007 | PCR-RFLP | 110 | 72 | 35 | 3 | 110 | 99 | 11 | 0 |
| Wang, 2010 | (28) | China | NM | PCR | 230 | 197 | 30 | 3 | 158 | 143 | 15 | 0 |
| Shi, 2011 | (29) | China | 2007 - 2009 | PCR-RFLP | 88 | 30 | 43 | 15 | 88 | 45 | 35 | 8 |
| Shi, 2012 | (30) | China | 2000 - 2010 | PCR-RFLP | 73 | 51 | 20 | 2 | 116 | 84 | 30 | 2 |
| Radwan, 2012 | (31) | Egypt | NM | PCR-RFLP | 128 | 82 | 42 | 4 | 160 | 136 | 24 | 0 |
| Talaat, 2012 | (14) | Egypt | NM | TaqMan | 45 | 42 | 2 | 1 | 45 | 25 | 13 | 7 |
| Teixeira, 2013 | (32) | Brazil | 2001-2009 | PCR | 111 | 81 | 30 | 0 | 202 | 173 | 26 | 3 |
| Saxena, 2013 | (33) | India | NM | PCR-RFLP | 59 | 52 | 7 | 0 | 139 | 128 | 11 | 0 |
| Feng, 2014 | (34) | China | 2010 - 2013 | PCR | 753 | 611 | 98 | 44 | 760 | 733 | 25 | 2 |
| Rizk, 2014 | (35) | Egypt | NM | PCR | 50 | 25 | 15 | 10 | 70 | 56 | 8 | 6 |
| Sghaier, 2015 | (36) | Tunis | 2012 - 2013 | PCR-RFLP | 100 | 25 | 47 | 28 | 200 | 80 | 72 | 48 |
ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the A Allele in Comparison to the G Allele (Allelic Model)
ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA Genotype Compared to the GG Gonotype (co-Dominant Effect)
Due its significant heterogeneity (Pheterogeneity = 0.006, I2 = 52%), a random model was used for the recessive model (Figure 4), showing a statistically significant association with the HCC risk (P < 0.047, OR [95% CI] =1.83 [1.01-3.33]). However, similar to the co-dominant model, its results were not trustworthy. After analyzing the results of selected articles for the dominant model, it was noted that there was a significant association between this model in TNF-α-308 and the risk of HCC development (P < 0.001, OR [95% CI] =1.80 [1.29-2.51]). This association is clearly shown in Figure 5. Considering the high heterogeneity (Pheterogeneity < 0.001, I2 = 81%) among the selected studies, the random model was used instead of the fixed model in the dominant model. Table 2 also summarizes the most important results for all four of the analyzed models.
ORs and CIs of HCC risk Associated With TNF-Α-308 G/A for the AA Genotype Compared to the AG + GG Genotype (Recessive Effect)
ORs and CIs of HCC risk Associated With TNF-α-308 G/A for the AA + AG Genotype Compared to the GG Genotype (Dominant Effect)
Summarized Results of Pooled ORs in the Meta-Analysis
| Model | No. of Studies | Employed Model | OR [95% CI] | P Value | Pheterogeneity | I2, % |
|---|---|---|---|---|---|---|
| A vs. G | 20 | Random | 1.77 [1.26-2.50] | < 0.002 | < 0.001 | 85 |
| AA vs. GG | 20 | Random | 2.14 [1.13-4.06] | < 0.020 | 0.003 | 55 |
| AA vs. AG + GG | 20 | Random | 1.83 [1.01-3.33] | < 0.047 | 0.006 | 52 |
| AA + AG vs. GG | 23 | Random | 1.80 [1.29-2.51] | < 0.001 | < 0.001 | 81 |
3.3. Sensitivity Analysis
After checking the effect of omitting any given study with a sensitivity analysis, the results of the allelic and dominant models were concluded to be completely reliable, while the other two models were considered unreliable because of alterations of the overall results in the sensitivity analysis. Figure 6 shows the sensitivity analysis results for the analyzed models.
Results of Sensitivity Analysis for the Four Models
3.4. Publication Bias
To evaluate for any evidence of publication bias among the included studies, funnel plots for all four of the models were performed (Figure 7). The shape of these plots suggested no evidence of publication bias among the studies.
Funnel Plot Analysis to Examine Publication Bias for all Analyzed Models
4. Conclusions
There are several risk factors for HCC development, including cirrhosis, HBV, HCV, toxins, drinking-water contamination, and alcohol (37). HCC most often develops as an outcome of HBV or HCV infections, which can be affected by various factors (38, 39). Various cytokines and cells are deeply involved in several types of diseases, such as HCC and viral hepatitis. Having a plan of their activity and functions may lead to the emergence of new therapeutic options and also better management of HBV infection (40, 41). For example, recently, Tavakolpour (41) used the function of cytokines and cells to introduce a new therapeutic approach for chronic HBV. Finding the association between TNF-α polymorphisms may also lead to the emergence of some options to better management of HCC. TNF-α is also involved in HCC development (42, 43). TNF-α polymorphisms can regulate the expression of this cytokine, and different meta-analyses have shown an association between TNF-α-308 G/A and the risk of HCC (44-47). However, the results for TNF-238 G/A in this context have been controversial (44-46, 48). Furthermore, there is limited evidence of an association between HCC and TNF-863 C/A, and no association between TNF-857 C/T or TNF-1031 T/C and the risk of HCC (19). Table 3 summarizes the results of recent meta-analyses that sought to identify links between HCC risk and different positions of TNF-α promoter.
Summary of Previous Meta-Analysis Results for Different TNF-α Promoter Positions
The present meta-analysis investigated associations between TNF-α-308 G/A and the risk of HCC in an allelic model and all genotype models. The results for the allelic model, reflecting 20 studies, indicated a significant association with HCC risk. This is similar to the results reported by Wang et al. (47), Hu et al. (46), and Cheng et al. (48). Due to high heterogeneity, the random model was employed for this analysis.
In addition to the A vs. G model, the AA vs. GG model was associated with HCC. However, Hu et al. (46) and Cheng et al. (48) did not report a relationship between this model and HCC risk. Thus, the present meta-analysis introduced an association between a co-dominant genotype model with HCC for the first time. However, a sensitivity analysis showed that these results should be considered unreliable. Thus, further studies are necessary to determine whether there is any significant association in this regard. In a recessive model, the P value was very close to 0.05, indicating statistical significance, but this was not trustworthy, as the sensitivity analysis found no association on the recessive model between HCC risk and TNF-α-308. Similar to our analysis, all of the published meta-analyses found no relationship on the recessive model.
For the dominant model, similar to all of the previously published meta-analyses, a significant association with HCC was found in the present study, confirming the previous results.
In all of the models, significant heterogeneity was observed. Thus, a random model was used for the analyses. In the allelic and dominant models, which were considered significantly associated with HCC in previous analyses, an association with HCC was also obtained in this study. However, this relationship may possibly exist in the co-dominant and recessive models. Differentiation of this result with previous studies was associated with the co-dominant model, which was not calculated in most of the other meta-analyses. Among all of the published results, Talaat’s study was considerably different from the others, reporting the G allele as a risk factor for HCC. This research was carried out in Egyptian patients with chronic HCV infections. Two other studies investigated Egyptian populations, but all of them introduced the A allele as a risk factor for HCC. Our results also confirmed the A allele risk factor. In other HCV cases that developed HCC, the results were not as different as they were in this study.
A sensitivity analysis, which removes one study and repeats the analysis, may reveal that the overall results depend on a certain study or not. After the sensitivity analysis in the present study, the reliability of the final results, which showed associations between the allelic and the dominant models with HCC, was confirmed. Despite an association of the co-dominant and recessive models with HCC, based on the sensitivity analysis results, this association was not trustworthy.
The present meta-analysis may suffer from certain limitations. First, only English-language studies were included, although there are studies published in other languages, especially Chinese. Another limitation is the high heterogeneity of the data, which can cause deviations from factual results. Environmental factors and primary diseases that cause HCC should also be considered, but this was impractical with the low number of included studies. In this analysis, it was assumed that all of the enrolled studies contained accurate data; however, this may not be true. On the other hand, there were also some advantages in this analysis that previous studies lacked. For example, this meta-analysis included 23 studies, which is the highest number among similar meta-analyses. The last update of the literature search was on July 12, 2015, which is considerably more recent than the last meta-analysis. To obtain more valid and reliable results, future studies are needed.
References
-
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. [PubMed ID: 21351269]. https://doi.org/10.1002/ijc.25516.
-
2.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38. [PubMed ID: 16879891]. https://doi.org/10.1016/j.jhep.2006.05.013.
-
3.
Jang MK, Su Kim H, Chung YH. Clinical aspects of tumor necrosis factor-α signaling in hepatocellular carcinoma. Curr Pharm Des. 2014;20(17):2799-808. https://doi.org/10.2174/13816128113199990587.
-
4.
Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29(11):1275-88. [PubMed ID: 18954521]. https://doi.org/10.1111/j.1745-7254.2008.00889.x.
-
5.
Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409-16. [PubMed ID: 16951987]. https://doi.org/10.1007/s10555-006-9005-3.
-
6.
Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei). 1999;62(6):327-33. [PubMed ID: 10389289].
-
7.
Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 1992;70(3):709-13. https://doi.org/10.1002/1097-0142(19920801)70:3<709::AID-CNCR2820700328>3.0.CO;2-O.
-
8.
Bortolami M, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, et al. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis. 2002;34(11):794-801. https://doi.org/10.1016/S1590-8658(02)80073-1.
-
9.
Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11(42):6624-30. [PubMed ID: 16425355].
-
10.
Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepat Mon. e35810. https://doi.org/10.5812/hepatmon.35810.
-
11.
Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992;1(5):353. [PubMed ID: 1363876].
-
12.
Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999;66(4):562-6. [PubMed ID: 10534109].
-
13.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci. 1997;94(7):3195-9. https://doi.org/10.1073/pnas.94.7.3195.
-
14.
Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI. Tumor necrosis factor-alpha-308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer. 2012;31(1):29-35.
-
15.
Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37(1):65-71. [PubMed ID: 12500190]. https://doi.org/10.1053/jhep.2003.50017.
-
16.
Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98(1):144-50. [PubMed ID: 12526950]. https://doi.org/10.1111/j.1572-0241.2003.07179.x.
-
17.
Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34(1):19-26. https://doi.org/10.1385/IJGC:34:1:19.
-
18.
Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control. 2004;15(7):657-63. [PubMed ID: 15280623]. https://doi.org/10.1023/B:CACO.0000036173.99930.75.
-
19.
Niro GA, Fontana R, Gioffreda D, Valvano MR, Lacobellis A, Facciorusso D, et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 2005;25(6):1175-81. [PubMed ID: 16343069]. https://doi.org/10.1111/j.1478-3231.2005.01166.x.
-
20.
Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505-10. [PubMed ID: 15763337]. https://doi.org/10.1016/j.jhep.2004.11.026.
-
21.
Chen CC, Yang SY, Liu CJ, Lin CL, Liaw YF, Lin SM, et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol. 2005;34(6):1310-8. [PubMed ID: 16172101]. https://doi.org/10.1093/ije/dyi191.
-
22.
Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14(12):841-8. [PubMed ID: 18070287]. https://doi.org/10.1111/j.1365-2893.2007.00880.x.
-
23.
Jeng JS, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9(11):987-92. https://doi.org/10.1593/neo.07781.
-
24.
Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, et al. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett. 2008;271(1):98-104. [PubMed ID: 18603357]. https://doi.org/10.1016/j.canlet.2008.05.036.
-
25.
Jeng JE, Tsai HR, Chuang LY, Tsai JF, Lin ZY, Hsieh MY, et al. Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore). 2009;88(6):349-57. [PubMed ID: 19910749]. https://doi.org/10.1097/MD.0b013e3181c10477.
-
26.
Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30(5):758-62. [PubMed ID: 19126646]. https://doi.org/10.1093/carcin/bgn286.
-
27.
Akkiz H, Bayram S, Bekar A, Ozdil B, Akgollu E, Sumbul AT, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol. 2009;33(3-4):261-4. [PubMed ID: 19683483]. https://doi.org/10.1016/j.canep.2009.06.001.
-
28.
Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, et al. A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology. 2010;42(7):674-80. [PubMed ID: 21080879]. https://doi.org/10.3109/00313025.2010.523696.
-
29.
Shi Z, Du C. Tumor necrosis factor alpha 308 G/A polymorphism and hepatocellular carcinoma risk in a Chinese population. Genet Test Mol Biomarkers. 2011;15(7-8):569-72. [PubMed ID: 21401328]. https://doi.org/10.1089/gtmb.2011.0008.
-
30.
Shi HZ, Ren P, Lu QJ, Niedrgethmnn M, Wu GY. Association between EGF, TGF-beta1 and TNF-alpha gene polymorphisms and hepatocellular carcinoma. Asian Pac J Cancer Prev. 2012;13(12):6217-20. [PubMed ID: 23464434].
-
31.
Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-beta1 and tumor necrosis factor-alpha genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60(1):271-6. [PubMed ID: 22682513]. https://doi.org/10.1016/j.cyto.2012.05.010.
-
32.
Teixeira AC, Mendes CJ, Marano LA, Deghaide NH, Secaf M, Elias JJ, et al. Alleles and genotypes of polymorphisms of IL-18, TNF-alpha and IFN-gamma are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil. Hum Immunol. 2013;74(8):1024-9. [PubMed ID: 23632060]. https://doi.org/10.1016/j.humimm.2013.04.029.
-
33.
Saxena R, Chawla YK, Verma I, Kaur J. IFN-gamma (+874) and not TNF-alpha (-308) is associated with HBV-HCC risk in India. Mol Cell Biochem. 2014;385(1-2):297-307. [PubMed ID: 24101445]. https://doi.org/10.1007/s11010-013-1838-9.
-
34.
Feng H, Kuai JH, Zhang MY, Wang GC, Shi YJ, Zhang JY. Tumor necrosis factor-alpha gene -308G > A polymorphism alters the risk of hepatocellular carcinoma in a Han Chinese population. Diagn Pathol. 2014;9:199. [PubMed ID: 25420786]. https://doi.org/10.1186/s13000-014-0199-3.
-
35.
Rizk EB, Amr ER, Mohamed Abd EM, Ghada A. Interleukin-1Beta and Tumor Necrosis Factor-Alpha Genes Polymorphism and Hepatocellular Carcinoma in Patients with Hepatitis C Virus in Egyptian Population. Indian J Appl Res. 2014;4(2).
-
36.
Sghaier I, Zidi S, Mouelhi L, Dabbech R, Ghazouani E, Brochot E, et al. The relationship between TNF alpha gene polymorphisms (-238/-308), TNF RII VNTR (p75) and outcomes of hepatitis B virus infection in Tunisian population. Gene. 2015;568(2):140-5. [PubMed ID: 25982858]. https://doi.org/10.1016/j.gene.2015.05.029.
-
37.
Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, et al. Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev. 2012;13(3):743-52. [PubMed ID: 22631642].
-
38.
Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon. 2013;13(7). https://doi.org/10.5812/hepatmon.8743.
-
39.
Civan J, Hann HW. Hepatitis C virus mediated hepatocellular carcinoma: a focused review for a time of changing therapeutic options. N Am J Med Sci. 2014;7(1):37. https://doi.org/10.7156/najms.2014.0701008.
-
40.
Tavakolpour S. The new insight into management of hepatitis B virus patients with flare. Immunology letters. 2016:173-77.
-
41.
Tavakolpour S. Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. Immunology letters. 2016;171:70-1.
-
42.
Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7(8):599-612. [PubMed ID: 17646865]. https://doi.org/10.1038/nrc2191.
-
43.
Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007;28(4):365-86. [PubMed ID: 17431229]. https://doi.org/10.1210/er.2006-0031.
-
44.
Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(6):947-52. [PubMed ID: 21107607]. https://doi.org/10.1007/s00432-010-0959-8.
-
45.
Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, et al. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci. 2011;56(8):2227-36. [PubMed ID: 21336601]. https://doi.org/10.1007/s10620-011-1617-y.
-
46.
Hu Q, Lou GG, Liu YC, Qian L, Lv BD. The Tumor Necrosis Factor-alpha-308 and -238 Polymorphisms and Risk of Hepatocellular Carcinoma for Asian Populations: A Meta-Analysis. Curr Ther Res Clin Exp. 2014;76:70-5. [PubMed ID: 25352937]. https://doi.org/10.1016/j.curtheres.2014.04.001.
-
47.
Wang F, Chen S, Xu R. WITHDRAWN: Association of TNF-α-308G> A polymorphisms with hepatocellular carcinoma in Han Chinese population: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014. https://doi.org/10.1016/j.clinre.2014.10.004.
-
48.
Cheng K, Zhao YJ, Liu L, Wan JJ. Tumor necrosis factor-alpha 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3275-9. [PubMed ID: 23803115].